MedTrace Logo

Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation

NCT03926845 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-04-06

No results posted yet for this study

Summary

Facial hyperpigmentation is a common skin issue that can cause embarrassment and affect the quality of life in majority of people. The investigators are conducting a research to study an efficacy and tolerability of Isobutylamido-thiazolyl-resorcinol 0.2% in lightening of the facial hyperpigmentation in comparison to vehicle intervention in 4, 8 and 12-week period. The ultimate goal is to provide the best cosmetic cream to improve the quality of life of people who suffer from facial hyperpigmentation.

Conditions

  • Facial Hyperpigmentation

Interventions

OTHER

Isobutylamido-thiazolyl-resorcinol Cream 0.2%

Each bottle contains Isobutylamido-thiazolyl-resorcinol cream 0.2% to be applied on the entire face twice daily for 12 weeks.

OTHER

Vehicle

Each bottle contains vehicle cream to be applied on the entire face twice daily for 12 weeks.

Sponsors & Collaborators

  • Beiersdorf (Thailand) Co., Ltd.

    collaborator UNKNOWN

  • Institute of Dermatology, Thailand

    lead OTHER_GOV

Principal Investigators

  • Chinmanat Lekhavat, MD · Institute of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-29
Primary Completion
2020-11-30
Completion
2021-01-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03926845 on ClinicalTrials.gov